Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Working Capital Changes (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Other Working Capital Changes data on record, last reported at -$1.7 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes changed N/A year-over-year to -$1.7 million; the TTM value through Dec 2025 reached -$1.7 million, down 636.48%, while the annual FY2025 figure was -$1.7 million, 636.48% down from the prior year.
  • Other Working Capital Changes reached -$1.7 million in Q4 2025 per TARS's latest filing, up from -$14.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $14.4 million in Q2 2025 and bottomed at -$14.4 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is $58823.5, with a median of $220000.0 recorded in 2023.
  • Peak YoY movement for Other Working Capital Changes: plummeted 497.67% in 2023, then surged 1636.66% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.4 million in 2021, then crashed by 42.39% to $795000.0 in 2022, then tumbled by 206.04% to -$843000.0 in 2023, then skyrocketed by 198.7% to $832000.0 in 2024, then crashed by 306.25% to -$1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$1.7 million in Q4 2025, -$14.4 million in Q3 2025, and $14.4 million in Q2 2025.